Semaglutide + Cagrilintide - CagriSema

1 Identity

Fixed-ratio two-component article: two acylated lipopeptides co-lyophilized, each bearing a C20 fatty diacid on a lysine side chain through its own linker chemistry, one C-terminal acid against one C-terminal amide, one disulfide present in cagrilintide only. Each component's full identity lives on its own record and is cross-referenced from here rather than restated. CAGRISEMA IS A sponsor'S name for A fixed combination of two molecules it owns, and a research-channel co-lyophilizate borrowing the word is not that article. Neither component name fixes a salt: both circulate as free base or free acid, as acetate and as trifluoroacetate, and every institutional listing writes the stoichiometry as X.

Sequence

Per component, cross-referenced. Semaglutide: 31-residue GLP-1(7-37) backbone with Aib8 and Arg34, Lys26 epsilon-acylated through AEEA-AEEA-gamma-Glu to octadecanedioic acid, free C-terminal glycine. Cagrilintide: 37 amino-acid residues, C-terminally amidated, one Cys-Cys disulfide, N-terminal lysine epsilon-acylated through a single gamma-Glu to eicosanedioic acid, no AEEA unit anywhere. Two AEEA against none is the linker fact that separates the two chains and it is not visible in either intact mass.

Molecular formula

Per component; a mixture has no combined formula and none is written. Semaglutide C187H291N45O59 (free acid); cagrilintide C194H312N54O59S2. The sulfur asymmetry is the most useful analytical fact about this pair: semaglutide contains no sulfur anywhere and cagrilintide contains two, so the isotope envelope assigns the two deconvoluted peaks without reference to retention time. Counterion is determined per component and independently; acetate on one against trifluoroacetate on the other passes a gross-weight check while the ratio is already out.

Average mass

Per component, on IUPAC 2021 abridged conventional atomic weights: semaglutide 4113.641 Da; cagrilintide 4409.069 Da. At the 1:1 by mass presentation - the ratio the sponsor's own fixed combination uses, at 2.4 mg plus 2.4 mg - A 10 mg plus 10 mg fill, 20 mg total nominal, IS 2.4309 and 2.2681 micromol, a molar ratio of 1.0718 : 1.0000. Equal mass is not equal moles, and the certificate states which basis the ratio criterion is written on. No single blend 'molecular weight' is printed, because a mixture does not have one.

Monoisotopic mass

Per component. Semaglutide 4111.11538 Da neutral; cagrilintide 4406.2515 Da neutral, 295.14 Da apart and never confusable with each other. Both are observed only multiply charged, so each requires a deconvoluted spectrum reported alongside the raw charge envelope. At 4 kDa a plus or minus 5 ppm window is about plus or minus 0.02 Da and excludes nothing that matters: it cannot resolve a single deamidation, and on cagrilintide it cannot resolve a reduced disulfide at +2.0157. Intact mass is read alongside the peptide map, never instead of it.

Salt / variant note

(1) ratio: no research-channel standard. The sponsor's fixed combination is 1:1 at 2.4 mg plus 2.4 mg; the channel listing recorded here is 5 mg plus 5 mg. (2) salt, per component and independently: free acid or free base, acetate, trifluoroacetate, stoichiometry written as X in the institutional catalogs and therefore unfixed. (3) des-acyl of either component is a specified impurity, not a lesser grade. (4) cagrilintide reduced form, disulfide open, +2.0157 Da, a separate species and a named attribute.

2 Class & testing panel

Form

Fixed-ratio blend

Testing panel

P2 — panel definitionfor both components, run per component and never once for the vial, with a mandatory P3 element contributed by semaglutide's Aib8 and a disulfide attribute contributed by cagrilintide alone. The union is not the sum of two simple panels: acylation site, des-acyl content and linker integrity are per-component determinations, and disulfide assignment applies to one component while the other contains no sulfur atom at all

3 Primary sources & evidence

The index reports the design and provenance of the literature, not a conclusion about effect.

Published literature exists for each component and is graded on that component's record. The fixed combination additionally carries a large registered phase 3 program, and Novo Nordisk A/S filed a New Drug Application with FDA for it on 18 December 2025. None of that is literature about a research-channel co-lyophilizate at an unstandardized ratio, and no published specification for one was located.

4 Storage & specification

Storage

Both components are surface-active C20-diacid conjugates that adsorb to glass, so the article is held in low-adsorption vials at minus 20 degrees C plus or minus 5 degrees C, desiccated and light-protected, with recovery demonstrated on the actual container-closure system. Cagrilintide adds reducing conditions and elevated pH as handling risks.

Shelf life

A 24-month interval at minus 20 degrees C plus or minus 5 degrees C is the starting assumption for either component alone, and the blend inherits neither component study: it is dated on its own stability protocol, run on the blend as filled. The attributes that limit that interval are per-component content, the component ratio, des-acyl content on each component and cagrilintide disulfide integrity.